The Zhitong Finance App learned that Kanglong Chemical (03759) rose more than 3%. As of press release, it had risen 3.86% to HK$27.96, with a turnover of HK$159 million.
According to the news, Kanglong Huacheng recently disclosed third-quarter results. Huaxi Securities indicated that Kanglong Huacheng's third-quarter results slightly exceeded expectations. The company achieved operating income of 120.0 billion yuan in 26Q1-3, up 19.0% year on year; realized net profit to mother of 1,247 billion yuan, up 9.3% year on year; realized deducted non-net profit of 1,181 billion yuan, up 14.2% year on year; realized adjusted net profit from non-IFRS was 1,496 billion yuan, up 21.97% year on year.
The bank continued that Kanglong Chemical's laboratory business achieved revenue of 2.59 billion yuan in 26Q3, an increase of 17.5% over the previous year, continuing the trend of marginal improvement. Considering the growth rate of new orders signed in 26Q1-3 by more than 25%, the future performance growth of the company's laboratory business is highly certain. The CDMO business achieved revenue of 1.22 billion yuan in 26Q3, an increase of 30.1% over the previous year, and along with the continued advancement of the company's small-molecule CDMO pipeline, the company expects demand for mid- to late-stage clinical and commercialization projects to maintain strong growth in the future, and considering the growth rate of new orders in the CDMO business of more than 40%, it is determined that the company's performance will continue to grow rapidly in the next few years.